Circle has introduced three developer kits for its Arc blockchain that enable apps to embed USDC and EURC stablecoin purchases, lending via the Morpho protocol, and Bitcoin-backed loans using cirBTC collateral without needing to write smart contracts. These kits simplify adding financial features to consumer apps by handling payments, KYC, and lending infrastructure. This move follows Arc's recent mainnet launch, which has already seen significant stablecoin activity. The success of these kits will depend on adoption by apps and growth in stablecoin circulation and lending on Arc.
Circle's new developer kits for stablecoin purchases and lending on Arc provide context for digital asset activity. For readers following the broader crypto market, here is Pluang's snapshot as of Oct 01, 2026 01:11 WIB: Of 50 major cryptocurrencies priced on Pluang, 33 rose and 15 fell. Notable movers include EOS with a price of Rp12.649 up 8.13%, SUSHI at Rp4.968 rising 6.81%, and ONE at Rp40 down 8.98%.
XRP's price recovered above $1.50 following a shareholder vote approving Evernorth's merger with Armada Acquisition Corp. II, which advances the Ripple-backed company's plan to list on Nasdaq under the ticker XRPN. The merger approval is a key step t...
Cardinal Health reported robust fiscal year 2026 results, including 14% revenue growth, a 20% increase in gross margin, and doubled free cash flow. Despite challenges like thin margins and higher current liabilities, the company remains strong with F...
At OpenAI's Dev Day, CEO Sam Altman introduced the Decisions API, a tool that allows AI models to quickly choose from predefined options, enhancing speed and reducing costs. This API is similar to TypeSafe AI's Jev, which is designed for fast, effici...
LayerZero has strengthened its role in regulated stablecoins through new institutional partnerships, including Anchorage Digital for Tether’s USAT stablecoin and BDACS for a Korean won-backed stablecoin. These integrations expand LayerZero’s infrastr...
Liquidia Corporation's main product, YUTREPIA, is showing promising growth and generating significant cash flow since its approval in May 2025. This success provides a solid operating foundation for the company's future expansion in pulmonary hyperte...
